Shareholder Accuses Acadia of Hiding Nuplazid Safety Issues

Acadia Pharmaceuticals Inc. is facing a securities class action alleging it hid safety concerns about its antipsychotic drug Nuplazid and improperly paid doctors to prescribe it.

The lawsuit, filed in a California federal court, alleges Acadia failed to disclose adverse events involving Nuplazid, including reported deaths during clinical trials leading up to Food and Drug Administration approval and after the drug went on the market. The suit, citing news reports, also claims the company gave millions in consulting, speaking, and travel payments to doctors who appeared to have prescribed Nuplazid more than others.

The market has battered Acadia this ...